|
pubmed:abstractText |
Sorafenib, a multikinase inhibitor of Raf and several growth factor receptors, is under investigation in combination with dacarbazine, a commonly used chemotherapeutic agent for the treatment of many cancers. The current phase I study investigates the effects of sorafenib on the pharmacokinetic (PK) profile of dacarbazine and its metabolite 5-amino-imidazole-4-carboxamide (AIC). (AIC is formed in amounts equimolar to the active alkylating moiety, methane diazohydroxide, which is undetectable by known validated assays.)
|
|
pubmed:affiliation |
Bayer HealthCare AG, Research Center, Building 431, Aprather Weg, 42096 Wuppertal, Germany. erich.brendel@bayerhealthcare.com
|
